Skip to main content

P53-dependent Metabolic and Epigenetic Reprogramming in Carcinogenesis

Project description

A guardian angel turned devilish could reveal therapeutic targets for many cancers

Cancer is diverse and complex but many cancers show certain similarities. Mutations in the TP53 gene coding tumour protein 53 (p53) are most commonly associated with human cancers. As the 'guardian of the genome', p53 regulates cell division and acts as a tumour suppressor, stopping cells with mutated or damaged DNA from dividing. In addition, TP53 mutation alters cell metabolism, which in turn, can affect modifications to DNA that control gene expression (epigenetics), resulting in abnormal gene expression that further promotes cancer development. MetEpiC is investigating this cycle of interactions for a clearer understanding of pathways with implications for therapeutically targeting several types of cancers.

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 196 707,84
Address
Rue De Tolbiac 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,00